# Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19

> **NCT04385186** · PHASE2 · UNKNOWN · sponsor: **National Blood Center Foundation, Hemolife** · enrollment: 60 (estimated)

## Conditions studied

- Infections, Coronavirus

## Interventions

- **DRUG:** Inactivated convalescent plasma
- **DRUG:** Support treatment

## Key facts

- **NCT ID:** NCT04385186
- **Lead sponsor:** National Blood Center Foundation, Hemolife
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-20
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04385186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04385186, "Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04385186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*